Biblio

Author Title Type [ Year

]

Filters: Author is Onizuka, Makoto [Clear All Filters]

2024

Konuma T, Harada K, Shinohara A, Uchida N, Shingai N, Ito A, Ozawa Y, Tanaka M, Sawa M, Onizuka M, et al. Association of individual comorbidities with outcomes in allogeneic hematopoietic cell transplantation from unrelated adult donors versus unrelated cord blood: A study on behalf of the Donor/Source and Transplant Complications Working Groups of the Japane. Am J Hematol. 2024.

Kurosawa S, Fukuda T, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Yoshimitsu M, Ishimaru F, Sato A, et al. Center effect on allogeneic hematopoietic stem cell transplantation outcomes for B-cell acute lymphoblastic leukemia. Cytotherapy. 2024.

Fukushima K, Kudo H, Oka K, Hayashi A, Onizuka M, Kusakabe S, Hino A, Takahashi M, Takeda K, Mori M, et al. Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation. Bone Marrow Transplant. 2024.

Fukunaga K, Ikegame K, Nakamae H, Doki N, Fukuda T, Kondo Y, Ara T, Eto T, Mori Y, Matsuoka K-I, et al. HLA haploidentical stem cell transplantation from HLA homozygous donors to HLA heterozygous donors may have lower survival rates than haploidentical transplantation from HLA heterozygous donors to HLA heterozygous donors: a retrospective nationwide analys. Int J Hematol. 2024.

Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, et al. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024.

Shimomura Y, Kitamura T, Murata M, Matsuo K, Ito Y, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, et al. Impact of center volume on chronic graft versus host disease in patients with allogeneic stem cell transplantation. Transplant Cell Ther. 2024.

Shibata S, Arai Y, Kondo T, Mizuno S, Yamasaki S, Akasaka T, Doki N, Ota S, Maruyama Y, Matsuoka K-I, et al. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy. 2024.

Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, et al. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2024.

Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, et al. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. Int J Hematol. 2024.

Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, et al. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Ann Hematol. 2024.

2023

Yanagisawa R, Koyama H, Yakushijin K, Uchida N, Jinguji A, Takeda W, Nishida T, Tanaka M, Eto T, Ohigashi H, et al. Analysis of risk factors for fatal renal complications after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2023.

Onizuka M, Kikkawa E, Machida S, Toyosaki M, Suzuki R, Ogiya D, Aoyama Y, Amaki J, Harada K, Hara R, et al. Association of deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia. Blood Cell Ther. 2023;6(3):80-86.

Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. Author Correction: A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):89.

Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, et al. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023.

Konuma T, Yamasaki S, Ishiyama K, Mizuno S, Hayashi H, Uchida N, Shimabukuro M, Tanaka M, Kuriyama T, Onizuka M, et al. Comparison of allogeneic transplant outcomes between matched sibling donors and alternative donors in patients over 50 years of age with acute myeloid leukemia: 8/8 allele-matched unrelated donors and unrelated cord blood provide better leukemia-free surv. Transplant Cell Ther. 2023.

Onishi Y, Mori T, Yamazaki H, Hiramoto N, Zaimoku Y, Kanaya M, Matsue K, Onizuka M, Aotsuka N, Uchida N, et al. Comparison of haploidentical stem cell transplantation with post-transplant cyclophosphamide versus umbilical cord blood transplantation in adult patients with aplastic anemia. Transplant Cell Ther. 2023.

Jo T, Arai Y, Kanda J, Kondo T, Ikegame K, Uchida N, Doki N, Fukuda T, Ozawa Y, Tanaka M, et al. A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Commun Med (Lond). 2023;3(1):67.

Imahashi N, Kurita N, Konuma T, Takahashi S, Nishida T, Tanaka M, Nakamae H, Kawakita T, Ota S, Doki N, et al. Effect of conditioning regimens and GVHD prophylaxis on the outcomes of umbilical cord blood transplantation performed with cyclophosphamide/total-body irradiation-based regimens. Transplant Cell Ther. 2023.

Konuma T, Matsuda K, Shimomura Y, Tanoue S, Sugita J, Inamoto Y, Hirayama M, Ara T, Nakamae H, Ota S, et al. Effect of graft-versus-host disease on posttransplant outcomes following single cord blood transplantation in comparison to haploidentical transplantation with posttransplant cyclophosphamide for adult acute myeloid leukemia. Transplant Cell Ther. 2023.

Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim S-W, Ara T, Mizuno I, Kuriyama T, et al. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2023.

Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, et al. Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome. Am J Hematol. 2023.

Tamaki M, Akahoshi Y, Ashizawa M, Misaki Y, Koi S, Kim S-W, Ozawa Y, Fujiwara S-I, Kako S, Matsuoka K-I, et al. Impact of anti-thymocyte globulin on survival outcomes in female-to-male allogeneic hematopoietic stem cell transplantation. Sci Rep. 2023;13(1):7166.

Hara R, Machida S, Hashimoto N, Ogiya D, Kawai H, Kawakami S, Shiraiwa S, Onizuka M, Ogawa Y, Kawada H, et al. Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax. Int J Hematol. 2023.

Araie H, Arai Y, Kida M, Aoki J, Uchida N, Doki N, Fukuda T, Tanaka M, Ozawa Y, Sawa M, et al. Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy. Ann Hematol. 2023.

Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujihara S, et al. Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A KSGCT Multicenter Analysis. Int J Infect Dis. 2023.

Pages